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Background
In the biopharmaceutical industry, process development
and optimization is key to produce high quality recom-
binant proteins at high yields. As technologies mature,
pressure on cost and timelines becomes greater for deli-
vering scalable and robust processes. Overall, process
development should be viewed as a continuum from the
early stages up to process validation. Here we outline a
lean approach on upstream development during the
initial phases to optimize yields while maintaining the
desired product quality profiles. Early-stage process
development was designed to lead to the establishment
of a baseline process and to systematically include
experiments with input parameters that have a high
impact on performance and quality. At this stage, poten-
tial for pre-harvest titer and yield increases as well as
product quality challenges were identified. Feed adjust-
ments and systematic experiments with top, high, and
medium impact parameters have then been performed
to develop a robust and scalable process. This approach
was applied to two early stage upstream processes.
Materials and methods
2L and 80L stirred tank bioreactors were run for 14 days
in a fed-batch mode in a chemically defined medium.
Feed was added daily from day 3 onwards. If required,
antifoam C was added to the bioreactor by manual injec-
tions. DO, pH, and temperature were controlled at set-
point. DO was controlled using a multi-stage aeration
cascade via a ring sparger. Viable cell concentration, cell
viability, and average cell diameter were measured using
a ViCell cell counter. The glucose, lactate, glutamine and
ammonia concentrations were measured with a BioPro-
file Analyzer 400. On the day of harvest, the clarification
was performed by centrifugation plus depth filtration.
Monoclonal Antibody (MAb) concentration of the super-
natant samples was quantified using Protein A high per-
formance liquid chromatography.
Results
A lean and Quality by Design (QbD) approach on pro-
cess development during the initial phases to optimize
yields while maintaining the desired product quality pro-
files was adopted. In this approach, a workpackage
including the expected high impact parameters (feeding
strategy, seeding density, pH, temperature and the inter-
action studies) was defined. This workpackage was
applied to the process development of a cell line 1 produ-
cing a monoclonal antibody and led to a 36% increase in
the monoclonal antibody titer compared to control con-
dition (data not shown). Then, the operational process
parameters and feeding strategy developed for cell line 1
(process 1) were applied to a cell line 2 producing a
monoclonal antibody fragment. The application of the
process 1 strategy to a cell line 2 was not the best for cell
line 2 and led to high pCO2 level, high ammonia concen-
tration, high osmolalities and low monoclonal antibody
fragment titers (Figure 1). A feeding strategy was opti-
mized for cell line 2 and pH set-point and deadband
were also adjusted in order to decrease the pCO2 level.
This optimized process for cell line 2 led to higher per-
formances (pCO2, ammonia concentration, and osmolal-
ities values were maintained at a low level) with a 43%
increase in the monoclonal antibody fragment titer (data
not shown). Then both processes were scaled up to 80L
stirred tank bioreactors and comparable monoclonal anti-
body titers were obtained at 2L scale and 80L scale
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(Table 1). For the cell line 1, Product Quality Attributes
such as Acidic Peak Group, aggregate and Mannose 5
were assessed and were maintained within the expected
ranges with scale-up (data not shown).
Conclusions
A similar process development approach was applied to
both projects where identical high impact parameters
Figure 1 Viable cell concentration and off-line pH, pCO2, osmolality, lactate and ammonia profiles during fed-batch culture (solid
black line: cell line 2, process 1 strategy, short dash line: cell line 1, process 1, long dash line: cell line 2, process 2)
Table 1 Comparison of MAb titers (normalized) obtained
for both cell lines at 2L scale and 80L scale
Cell line 1, Process 1 Cell line 2, Process 2
2L scale 1.00 1.00
80L scale 0.99 1.09
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were identified. Although process optimized for cell line
1 was not the best for cell line 2, we were able to use it
as a starting point and were able to optimize within the
tight timelines. For both projects, high titers were
achieved following our lean approach on process devel-
opment. The final process 1 optimized for a cell line 1
led to a 36% increase in monoclonal antibody titer. The
final process 2 optimized for a cell line 2 led to a 43%
increase in monoclonal antibody fragment titer. Com-
parable titers and product quality attributes were
observed at 2L scale and 80L scale. Hence the adopted
feeding strategy proved to be robust and scalable.
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